Alterity flags ATH434 Phase 3, ASX talk set

Alterity Therapeutics plans an ASX SMIDcaps Conference presentation and highlights progress toward a Phase 3 MSA trial for lead drug ATH434.

Rhea-AI Filing Summary

Alterity Therapeutics Limited (ATHE) reported that Non-Executive Director Lawrence Gozlan will present at the ASX SMIDcaps Conference on September 23, 2026 at 1:55 p.m. AEST, with access to registration and an archived webcast available via the company’s website under Investors: Events and Presentations.

Alterity describes itself as a clinical stage biotechnology company developing disease modifying therapies for neurodegenerative diseases, with a focus on Multiple System Atrophy and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial of its lead asset ATH434 in MSA, following clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data from an open label Phase 2 trial in advanced MSA.

Key Figures

Conference presentation date: September 23, 2026 Conference presentation time: 1:55 p.m. AEST Phase of upcoming pivotal trial: Phase 3 +2 more

5 metrics

Conference presentation date September 23, 2026 Scheduled date of Alterity’s presentation at the ASX SMIDcaps Conference

Conference presentation time 1:55 p.m. AEST Scheduled time of the ASX SMIDcaps Conference presentation by Lawrence Gozlan

Phase of upcoming pivotal trial Phase 3 Planned pivotal trial in Multiple System Atrophy for lead asset ATH434

Phase of prior randomized controlled trial Phase 2 Randomized, double-blind, placebo-controlled trial of ATH434 in MSA

Phase of open label trial Phase 2 Open label clinical trial of ATH434 in participants with advanced MSA

Key Terms

Form 6-K, Multiple System Atrophy, Phase 3 pivotal trial, randomized, double-blind, placebo-controlled, +2 more

6 terms

Form 6-K regulatory

"SECURITIES AND EXCHANGE COMMISSION FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Multiple System Atrophy medical

"developing disease modifying therapies in Multiple System Atrophy (MSA) and related"

A progressive neurological disorder that damages multiple areas of the nervous system, causing problems with movement, balance and involuntary functions like blood pressure and bladder control; think of it as critical wiring in the body slowly failing. Investors care because the condition defines the size and urgency of the market for treatments, influences clinical trial difficulty and regulatory risk, and can lead to high per-patient pricing but also greater development uncertainty.

Phase 3 pivotal trial medical

"Alterity is preparing to initiate a Phase 3 pivotal trial in MSA"

A phase 3 pivotal trial is the large, final clinical study that tests whether a new drug or medical treatment works and is safe enough for regulators to approve it for widespread use. Think of it as the full-scale dress rehearsal before a product launches: positive results can unlock regulatory approval and big commercial upside, while failures can halt a program and significantly affect investor value.

randomized, double-blind, placebo-controlled medical

"has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

open label Phase 2 clinical trial medical

"reported positive data in its open label Phase 2 clinical trial in participants"

development stage enterprise financial

"ALTERITY THERAPEUTICS LIMITED (a development stage enterprise)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ALTERITY THERAPEUTICS LTD (ATHE) announce in this Form 6-K?

Alterity Therapeutics announced that Non-Executive Director Lawrence Gozlan will present at the ASX SMIDcaps Conference on September 23, 2026, and that investors can access registration and an archived webcast through the company’s website under Investors: Events and Presentations.

When and at what time will ATHE present at the ASX SMIDcaps Conference?

Alterity’s presentation at the ASX SMIDcaps Conference is scheduled for September 23, 2026 at 1:55 p.m. AEST. The company states that an event registration link and archived webcast will be available on its website in the Investors: Events and Presentations section.

What is the main therapeutic focus of Alterity Therapeutics (ATHE)?

Alterity Therapeutics is focused on developing disease modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders. It positions itself as a clinical stage biotechnology company working on treatments for neurodegenerative diseases.

What stage is Alterity’s lead asset ATH434 in, according to this filing?

Alterity states it is preparing to initiate a Phase 3 pivotal trial of ATH434 in Multiple System Atrophy. ATH434 has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open label Phase 2 trial in advanced MSA.

Where is Alterity Therapeutics (ATHE) based and on which exchanges is it listed?

Alterity Therapeutics notes that it is based in Melbourne, Australia and San Francisco, California, USA. It lists its securities as trading on the ASX under ATH and on NASDAQ under ATHE.

How can investors and media contact Alterity Therapeutics (ATHE)?

The filing lists investor contacts Elyse Shapiro and Remy Bernarda via ir@alteritytx.com and +1 (415) 203-6386, and media contacts Melissa Tempra and Casey McDonald at melissa@nwrcommunications.com.au and cmcdonald@tiberend.com with phone +1 (646) 577-8520.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 06:03 AM Accepted by SEC EDGAR 09/18/2026 - 06:01 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

99.1 Alterity Therapeutics to Present at ASX SMIDcaps Conference

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alterity Therapeutics Limited
	By:	/s/ Julian Babarczy
		Julian Babarczy
		Chairman

Date: September 18, 2026

2

Exhibit 99.1

Alterity Therapeutics to Present at the ASX SMIDcaps Conference

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 18 September 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Lawrence Gozlan, Non-Executive Director, will present at the ASX SMIDcaps Conference on Wednesday, September 23, 2026 at 1:55 p.m. AEST.

A link to the event registration and archived webcast may be accessed on Alterity Therapeutics website under the Investors section: Events and Presentations.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors

Elyse Shapiro

ir@alteritytx.com

Remy Bernarda

Investor Relations Advisory Solutions

ir@alteritytx.com

+1 (415) 203-6386

Media

Melissa Tempra

NWR Communications

melissa@nwrcommunications.com.au

Casey McDonald

Tiberend Strategic Advisors, Inc.

cmcdonald@tiberend.com

+1 (646) 577-8520

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 8.3 KB